Company Encyclopedia
View More
name
Anti-Pandemic Concept
CP00007.US
News
View More

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck's experimental oral HIV treatment, combining doravirine and islatravir, proved non-inferior to Gilead's Biktarvy in a late-stage trial for adults with HIV-1 who hadn't received prior treatment. The safety profile was comparable, and Merck plans to present detailed findings at a medical meeting and submit applications to health authorities. The FDA decision on approval is expected by April 28, 2026. Doravirine is already approved in the U.S., while islatravir is still experimental.

Reuters·
US
GILD
+2.49%
Reuters·
US
GILD
+2.49%

Lakeland Industries Expands with New 8,000-Square-Foot California Facility

Lakeland Industries Inc. has expanded its service platform by leasing a new 8,000-square-foot facility in Fresno, California. This expansion, through its subsidiary California PPE Recon, Inc., aims to enhance operational capacity and service offerings for the firefighting market. The new facility will support growth by improving service levels, accelerating turnaround times, and enabling new offerings such as rental gear programs, training, and consulting. This move is expected to strengthen customer relationships and position Lakeland for future growth in public safety markets.

Reuters·
US
LAKE
-0.62%
Reuters·
US
LAKE
-0.62%

Gilead Sciences Announces Departure of Executive Vice President Deborah H. Telman

Gilead Sciences Inc. announced that Deborah H. Telman will step down as Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025. Her employment with the company will end later in the month.

Reuters·
US
GILD
+2.49%
Reuters·
US
GILD
+2.49%

Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing

03:26 AM EST, 11/19/2025 (MT Newswires) -- Johanna Mercier, Chief Commercial Officer, on November 17, 2025, sold 28,000 shares in Gilead Sciences ( GILD ) for $3,524,173. Following the Form 4 filing with the SEC, Mercier has control over a total of 107,193 common shares of the company, with 107,193 shares held directly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity·
US
GILD
+2.49%
fidelity·
US
GILD
+2.49%

Top Executive Sells Thousands of Vir Biotechnology Shares!

EVP & CFO Jason O’Byrne of Vir Biotechnology sold 6,799 shares worth $37,734 on November 18, 2025. Despite positive trial results and a strong cash position, Vir faces financial losses and high R&D expenses. Analysts have a neutral outlook due to these financial challenges. The stock has a bearish technical sentiment and a -24.48% YTD performance.

Tip Ranks·
US
VIR
+0.18%
Tip Ranks·
US
VIR
+0.18%
Posts
View More